Evidence map›Paper›PMID 27295567›Full record

ArticleBiochimica et biophysica acta2016

MDR1 mediated chemoresistance: BMI1 and TIP60 in action.

Soumyajit Banerjee Mustafi, Prabir Kumar Chakraborty, Sarwat Naz, Shailendra Kumar Dhar Dwivedi, Mark Street, Rumki Basak, Da Yang, Kai Ding, Priyabrata Mukherjee, Resham Bhattacharya

Abstract read
In one paragraph

Article in Biochimica et biophysica acta, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Soumyajit Banerjee MustafiPeggy and Charles Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.
Prabir Kumar ChakrabortyPeggy and Charles Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; Department of Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.
Sarwat NazPeggy and Charles Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.
Shailendra Kumar Dhar DwivediPeggy and Charles Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.
Mark StreetPeggy and Charles Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.
Rumki BasakPeggy and Charles Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.
Da YangCenter for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA; Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Computational & Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA.
Kai DingDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Priyabrata MukherjeePeggy and Charles Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; Department of Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.
Resham BhattacharyaPeggy and Charles Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; Department of Cell Biology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA.
University of Oklahoma Health Sciences Center · USUniversity of Oklahoma · USUPMC Hillman Cancer Center · US

Funding

Cystathionine beta synthase (CBS) and angiogenesisR01HL120585 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BHATTACHARYA, RESHAM, MUKHERJEE, PRIYABRATA · 2013 to 2017
$2.1M
Bmi-1, a potential therapeutic target in ovarian cancerR01CA157481 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BHATTACHARYA, RESHAM · 2012 to 2016
$1.6M
Exploiting gold nanoparticle as a probe to identify therapeutic targetsR01CA260449 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Resham Bhattacharya, Priyabrata Mukherjee · 2022 to 2026
$1.6M
NCI NIH HHS R01 CA157481NCI NIH HHS R01 CA260449NHLBI NIH HHS R01 HL120585
6 · The paper itself

Abstract

Chemotherapy-induced emergence of drug resistant cells is frequently observed and is exemplified by the expression of family of drug resistance proteins including, multidrug resistance protein 1 (MDR1). However, a concise mechanism for chemotherapy-induced MDR1 expression is unclear. Mechanistically, mutational selection, epigenetic alteration, activation of the Wnt pathway or impaired p53 function have been implicated. The present study describes that the surviving fraction of cisplatin resistant cells co- upregulate MDR1, BMI1 and acetyl transferase activity of TIP60. Using complementary gain and loss of function approaches, we demonstrate that the expression of MDR1 is positively regulated by BMI1, a stem-cell factor classically known as a transcriptional repressor. Our study establishes a functional interaction between TIP60 and BMI-1 resulting in upregulation of MDR1 expression. Chromatin immunoprecipitation (ChIP) assays further establish that the proximal MDR1 promoter responds to cisplatin in a BMI1 dependent manner. BMI1 interacts with a cluster of E-box elements on the MDR1 promoter and recruits TIP60 resulting in acetylation of histone H2A and H3. Collectively, our data establish a hitherto unknown liaison among MDR1, BMI1 and TIP60 and provide mechanistic insights into cisplatin-induced MDR1 expression resulting in acquired cross-resistance against paclitaxel, doxorubicin and likely other drugs. In conclusion, our results advocate utilizing anti-BMI1 strategies to alleviate acquired resistance to chemotherapy.

Indexed as

Gene Expression Regulation, NeoplasticAcetylationAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BCell Line, TumorCell SurvivalCisplatinDoxorubicinDrug Resistance, MultipleDrug Resistance, NeoplasmEpithelial CellsFemaleHistone AcetyltransferasesHistonesHumansLysine Acetyltransferase 5ABCB1 protein, humanAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BBMI1 protein, humanCisplatinDoxorubicinHistone AcetyltransferasesHistonesKAT5 protein, humanLysine Acetyltransferase 5PaclitaxelPolycomb Repressive Complex 1BMI1ChemoresistanceMDRTIP60

Identifiers

PMID27295567
PMCPMC4958591
OpenAlexW2422922467

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.